Patients with Bladder Cancer Report Continued Sexual Function After Radical Cystectomy

Researchers sought to better understand the impact of treatment on intimate relationships for patients with bladder cancer.

Patients who underwent radical cystectomy for bladder cancer reported continued sexual interest and activity, despite significant illness, according to research presented at the 21st Annual Meeting of the Society for Urologic Oncology.1

In particular, 53% of patients reported at least a little interest in sexual activity, with 40% endorsing sexual activity within the previous 4 weeks of completing the survey, which was the primary outcome of the study.

Investigators evaluated the sexual function of 150 patients undergoing radical cystectomy for bladder cancer in an effort to better understand how cancer treatment impacts sexual function and intimate partner relationships.

Patients were administered both The European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire–Bladder Cancer Muscle Invasive (EORTC QLQ–BLM 30) and Functional Assessment of Cancer Therapy–Bladder. Those who completed the sexual function subscale of the EORTC QLQ-BLM 30 (n = 132) were deemed eligible for the study.

The median age of all patients was 68.5 years, and 82% were male. The mean sexual function subscale score for all patients was 61.5 ± 25.2, with women having significantly worse mean scores of 72.9 ± 27.1 versus 59.1 ± 24.2 for men (P = .02)

On multivariate analysis, both age and female gender were independently associated with worse (higher) sexual function subscale scores.

When compared with women, men reported both higher rates of interest in sexual activity (57% vs 35%, respectively) and higher rates of sexual activity (43% vs 30%), with 33% of female responders admitting to feeling uncomfortable about being sexually intimate.

Investigators cited the lack of existing data regarding sexual function as the primary reason for conducting the study, noting that many urologists fail to discuss possible changes in sexual interest and function with patients prior to radical cystectomy. A lack of information regarding baseline sexual function was noted as a common barrier to initiating those conversations.

Noted limitations to the study were the relatively small sample size of female patients and an unknown meaningful clinical difference.

The authors stated that the results support a need for further investigation into the impact of surgery on sexual function, and that novel targeted interventions to improve outcomes may be needed.2

References

1. Westerman ME, Kokorovic A, Wang XS, et al. Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. Presented at: 21st Annual Meeting for the Society of Urologic Oncology; December 3, 2020. Poster 7.

2. Westerman ME, Kokorovic A, Wang XS, et al. Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. J Sex Med. 2020;17:1995–2004. doi:10.1016/j.jsxm.2020.06.015

Related Videos
Nazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
An expert from Chase Comprehensive Cancer Center discusses how findings from a genomic analysis of the phase 2 BLASST-1 trial may identify biomarkers of response and resistance to nivolumab/chemotherapy in muscle-invasive bladder cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Patients with kidney cancer should be made aware of trials that have not read out positively in the adjuvant setting, according to an expert from the Royal Free London NHS Foundation Trust.
Ongoing clinical trials are exploring the cytoreductive properties and immunogenic potential of stereotactic radiation in the treatment of patients with metastatic kidney cancer, according to an expert from the University of Texas Southwestern Medical Center.
“Much more research” is needed to advance the adjuvant treatment of patients with kidney cancer, according to an expert from the Royal Free London NHS Foundation Trust.
Related Content